Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Mechanistically-Specific Hypotheses: Aβ-Tau Synergy in Alzheimer's Disease\n\n---\n\n## Hypothesis 1: Prion-Like Cross-Seeding via Toxic Oligomer Interfaces\n\n**Title**: Aβ oligomers template tau nucleation\n\n**Mechanism**: Amyloid-β oligomers (particularly dodecameric Aβ*56) expose cryptic β-strand domains that directly interact with tau's R2/R3 microtubule-binding repeat domain, catalyzing conformational conversion into β-sheet-rich nuclei. This cross-seeding bypasses the slow homogeneous nucleation barrier, explaining why Aβ precedes and accelerates tau spreading. The formed tau seeds are then transmitted transsynaptically regardless of ongoing Aβ burden.\n\n**Key Evidence**: \n- Aβ-fibrils accelerate recombinant tau aggregation in vitro (PMID 28504677)\n-Human PET imaging demonstrates spatial correlation between early Aβ deposition and subsequent tau spread pattern (PMID 29044071)\n\n**Testable Prediction**: In a mouse model where Aβ is turned off after plaque formation, tau pathology will continue to propagate and spread if Aβ*56 oligomers are removed early—but will plateau if tau seeds have already invaded downstream brain regions.\n\n**Target Gene/Protein**: Aβ*56 oligomer / tau R2 domain interface\n\n---\n\n## Hypothesis 2: Kinase-Phosphatase Set-Point Disruption\n\n**Title**: Aβ permanently raises GSK3β activity\n\n**Mechanism**: Aβ42 oligomers trigger persistent activation of GSK3β (via PP2A inhibition and FYN-mediated tyrosine phosphorylation of GSK3β-Y216) while simultaneously inhibiting PP2A through POSTNSA-mediated recruitment. This creates a new kinase-phosphatase equilibrium biased toward tau hyperphosphorylation. Because GSK3β also phosphorylates Aβ-metabolizing enzymes (BACE1, IDE), this circuit generates more Aβ and more phospho-tau in a feed-forward loop.\n\n**Key Evidence**:\n- Post-mortem AD brain shows reduced PP2A activity and elevated active GSK3β (PMID 12431986)\n- GSK3β inhibition reduces both Aβ and tau pathology in 3xTg mice (PMID 18930951)\n\n**Testable Prediction**: Acute GSK3β inhibition in late-stage 3xTg mice will reduce tau phosphorylation but NOT restore PP2A activity or reduce Aβ—indicating the set-point is locked and requires earlier intervention.\n\n**Target Gene/Protein**: GSK",
  "tokens_used": "557"
}